SCHEMBL6599290

SCHEMBL6599290

COc1ccc(-n2cnnn2)cc1C(=O)N(C)CC(CCN1CCCN(c2nc3ccccc3n2Cc2ccco2)CC1)c1ccc(F)cc1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
HRH1 P35367 5/20 0.33
TACR2 P21452 3/20 0.33
CYP2D6 P10635 4/20 0.33
CHRM1 P11229 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 2/20 0.32
KCNH2 Q12809 3/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KCNJ1 P48048 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6597567 0.93 TACR2 (0.43) TACR2
SCHEMBL6594885 0.92 HRH1 (0.41) HRH1TACR2CYP2D6CHRM1KCNH2
SCHEMBL6599183 0.91 HRH1 (0.35) HRH1TACR2CYP2D6CHRM1KCNH2
SCHEMBL6596468 0.90 TACR2 (0.34) MAPTMEN1ALDH1A1KMT2AHRH1
SCHEMBL6598208 0.89 CHRM1 (0.37) HRH1TACR2CHRM1KCNH2
SCHEMBL6597082 0.89 MEN1 (0.34) MAPTMEN1ALDH1A1KMT2AHRH1
SCHEMBL6593690 0.89 DRD2 (0.36) TACR2DRD2DRD4DRD3
SCHEMBL6598377 0.89 TACR2 (0.34) MAPTMEN1ALDH1A1HTTKMT2A
SCHEMBL6598374 0.89 TACR2 (0.34) MAPTMEN1ALDH1A1HTTKMT2A
SCHEMBL6598788 0.88 TACR2 (0.34) MAPTTACR2KDM4ETSHRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0888338-B1 NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES AVENTIS PHARMA INC (US) 2004-11-17 EP disclosed